Peripheral blood progenitor cells (PBPCs) are increasingly used for autografting after high-dose chemotherapy. One advantage of PBPCs over the use of autologous bone marrow would be a reduced risk of tumor-cell contamination. However, the actual level of tumor cells contaminating PBPC harvests is poorly investigated. It is currently not known whether mobilization of PBPCs might also result in mobilization of tumor cells. We evaluated 358 peripheral blood samples from 46 patients with stage IV or high-risk stage 11/111 breast cancer, small cell (SCLC) or non-small cell (NSCLC) lung cancer, as well as other advanced malignancies for the detection of epithelial tumor cells. Monoclonal antibodies against acidic and basic cytokeratin components and epithelial antigens (HEA) were used in an alkaline phosphatase-anti-alkaline phosphatase assay with a sensitivity of 1 tumor cell within 4 X 1 Os total cells. Before initiation of PBPC mobilization, circulating tumor cells were detected in 2/7 (29%) patients with stage IV breast cancer and in 2/10 (20%) patients with extensivedisease SCLC, respectively. In these patients, an even higher number of circulating tumor cells was detected after chemotherapy with VP16, ifosfamide, and cisplatin (VIP) followed by granulocyte colony-stimulating factor ERIPHERAL BLOOD progenitor cells (PBPC) are increasingly used as an alternative to autologous bone marrow (BM) rescue for patients with solid tumors as well as hematologic malignancies."5 Advantages of this method over the use of autologous marrow include the ability to collect PBPCs without general anesthesia in an outpatient setting, the possibility to harvest progenitor cells in patients with BM fibrosis resulting from pelvic irradiation, and particularly, a more rapid hematopoietic r e~o v e r y .~.~ PBPCs can be harvested during the recovery phase after myelosuppressive ~hemotherapy,~ after administration of colonystimulating factors (CSFS),',~ or after chemotherapy plus CSFadrnini~tration.~~'~-'* At our institution, PBPCs are mobilized by conventional dose chemotherapy + CSFs to combine a treatment regimen with broad antitumor activity with the simultaneous mobilization of PBPCS.~.".'~ Moreover, chemotherapy + CSF induced mobilization results in higher numbers of progenitor cells'0*'' and there might be a possible advantage of a therapeutic chemotherapy regimen (G-CSF). This approach has previously been shown to be highly effective in mobilizing PBPCs. In the 42 patients without circulating tumor cells during steady state, tumor cells were mobilized in 9/42 (21 %) patients after VIP + G-CSF induced recruitment of PBPCs. The overall incidence of tumor cells varied between 4 and 5,600 per 1.6 X 1 OB mononuclear cells analyzed. All stage IV breast cancer patients and 50% of SCLC patients were found to concomitantly mobilize tumor cells and PBPCs. Kinetic analyses showed two patterns of tumor cell recruitment depending on the presence or absence of bone marrow disease: (1 ) early after chemotherapy (between days 1 and 7 ) in patients without marrow infiltration, and (2) between days 9 and 16 in patients with marrow infiltration, ie, within the optimal time period for the collection of PBPCs. We show that there is a high proportion of patients with circulating tumor cells under steady-state conditions, and in addition a substantial risk of concomitant tumor cell recruitment upon mobilization of PBPCs, particularly in stage IV breast cancer patients with bone marrow infiltration. The biologic and clinical significance of this finding is unknown at present. preceding the harvest of PBPCs in terms of reduced tumor cell contamination.
Although there are reports demonstrating the presence of circulating tumor cells in children with disseminated neurobla~toma,'~.'' in patients with lymph~ma,'~,'' or in patients with metastatic breast cancer,'* the actual risk of tumor cell contamination in preparations of mobilized PBPCs is not known. Therefore, we investigated whether tumor cells might be recruited concomitant with hematopoietic progenitor cells upon chemotherapy plus granulocyte CSF (G-CSF)-induced mobilization of PBPCs.
We applied a highly sensitive immunocytochemical assay for the detection of circulating tumor cells in patients with a variety of malignancies eligible for high-dose chemotherapy and PBPC transplantation. A total of 358 blood samples from 46 cancer patients were evaluated after mobilization of PBPCs by conventional-dose chemotherapy with VP16, ifosfamide, and cisplatin plus G-CSF administration. 6 We show that there is a substantial risk of tumor cell mobilization upon recruitment of PBPCs.
PATIENTS AND METHODS
Patients. Forty-six consecutive patients with histologically confirmed solid tumors were analyzed. The study protocol was a p proved by the institutional review board and all patients gave written informed consent. The following patients were included newly diagnosed extensive or limited disease small cell (SCLC, n = 17) or non-small cell (NSCLC, n = 12) lung cancer, stage IV breast cancer (n = 7), stage II/III (n = 2) breast cancer patients with more than 10 positive lymph nodes, as well as any other advanced solid tumor for which no standard treatment was available (n = 8; poorly differentiated carcinoma of unknown primary site and advanced head and neck cancer) ( Table I) . Standard-dose VIP chemotherapy + G-CSF for the mobilization of PBPCs. Patients were treated with standard-dose VP16 (500 mg/m2), ifosfamide (4 g/m2), and cisplatin (50 mg/m2) (VIP regimen) followed by the administration of G-CSF (Filgrastim, Neupogen; AMGEN, Munich, Germany; 5 pglkg SC starting day 1 after chemotherapy for 14 days), as described.6,'2 Serial samples of peripheral blood (n = 358) were analyzed after the first and/or second cycle of chemotherapy. Each patient was monitored before chemotherapy (steady state) and subsequently three times a week for the presence of tumor cells in peripheral blood samples. At least six blood samples were analyzed for each patient between day -2 and day + 18 after VIP chemotherapy.
Preparation and immunostaining on adhesion slides. Mononuclear cells (MNCs) from blood samples were isolated by density centrifugation through Ficoll/Hypaque (Pharmacia, Freiburg, Germany), washed twice in phosphate-buffered saline (PBS), and resuspended at 4 to 5 X lo6 cells/mL in PBS. Isolated MNCs were attached to Poly-L-lysine coated adhesion slides (Fa. Marienfeld, Bad Mergentheim, Germany) consisting of 3 spots with each 1.4 cm in diameter. Routinely, two slides with a total of 6 spots were examined for each patient and for each time point. One hundred microliters of the cell suspension was attached on each spot (=4 to 5 X IO5 cells/spot). After a 3-minute incubation, the slides were rinsed with PBS to remove dead cells and cellular debris. Subsequently, cells were air-dried for 24 hours and stored at -70'C until use. The cells were fixed in aceton/ethanol (10 minutes, 4°C) for subsequent marker analysis. For immunostaining, anticytokeratin (clone AEI/AE3, IgGI; Boehringer Mannheim, Mannheim, Germany, and clone KL 1, I g G I ; Dianova, Hamburg, Germany) as well as anti-epithelial (clone HEA 125, IgGI; Progen, Heidelberg, Germany) monoclonal antibodies (MoAbs) were used.
The anticytokeratin AEI/AE3 antibodies specifically recognize 40-to 56-kD proteins of the acidic as well as all members of the basic subfamily. The KLI antibody recognizes a 56-kD protein of the acidic subfamily. A mixture of both anticytokeratin antibodies (AEI/AE3 + KL1) was used. HEA 125 reacts with the 35-kD human epithelium-specific cell-surface glycoprotein. The immunostaining was performed after preincubation with normal serum, according to established procedures (APAAP assay; DAKO, Hamburg, Germany). To increase chromogen intensity, the antibody reaction was developed twice. Cells containing cytokeratin components or epithelial antigens were stained bright red. Each immunostaining assay contained a negative as well as a positive control. One spot with an IgG 1 isotype served as a negative control, one spot with a human breast cancer cell line (MCF7; kindly provided by H.H. Fiebig, Freiburg, Germany) served as a positive control. A total of 4 spots with at least 1.6 X I O6 total cells were analyzed for the presence of tumor cells using a standard microscope. The total number of cells present on each spot was calculated by counting the cell number within I8 quadrants out of 8 I total quadrants using a special grid within the ocular. Based on a statistical model, the error in the calculated cell number was less than 6%.
RESULTS
The APAAP assay was performed with anticytokeratin antibodies (AEI/AE3, KLI) and an epithelial cell antibody (HEA 125) and is used diagnostically in our department for the detection of epithelial tumor cells in both BM specimen, as well as pleural and peritoneal effusions. In addition to anticytokeratin antibodies, we also evaluated antichromogranin, antisynaptophysin, and antineuron specific enolase (NSE) antibodies that, however, did not show reproducible results in our laboratory. Therefore, AEI/AE3, KLI, and HEA 125 were the antibodies used in this study because of their strong staining with epithelial tumor cells. Normal peripheral blood MNCs (as studied in 18 volunteers) as well as BM and peripheral blood specimens from patients with hematologic disorders (as studied in 32 patients) were nonreactive with anticytokeratin and HEA 125 antibodies. In some cases plasma cells were stained weakly by HEA-125; these cells could be easily discriminated from tumor cells by morphologic criteria.
To establish the sensitivity of this assay, we analyzed single cell suspensions of a human small cell lung cancer (LXFS 428/ 15) and a human breast cancer (MCF-7) xenograft from nude mice in normal peripheral blood or BM MNCs. The sensitivity of this assay was 1:4 X lo5, as analyzed by the detection of AE 1/AE3 + KLI and HEA 125 positive human LXFS or MCF-7 tumor cells within normal peripheral blood or BM MNCs (Fig 1) .
Before initiation of PBPC mobilization, baseline samples from all 46 patients were examined for the presence of cytokeratin and HEA 125-positive circulating cells ( Table 1) . The overall frequency of immunocytochemically positive blood samples before chemotherapy was 8.7%. In contrast, BM specimens were found to be cytokeratin-and/or HEApositive in 17.4% of these patients.
Upon VIP chemotherapy + G-CSF-induced mobilization of PBPCs, cytokeratin-and/or HEA-positive tumor cells were recruited in a total of 13 patients (28.3%). In the four patients already shown to be positive for circulating tumor cells under steady-state conditions, additional tumor cells were recruited into peripheral blood, with higher total numbers when compared with baseline. In the patients without evidence of circulating tumor cells at baseline (n = 42), tumor cells were recruited in nine patients (2 I .4%).
Dependent on the presence or absence of BM infiltration, different kinetics of tumor cell mobilization were observed: in patients without BM disease, tumor cells were mobilized only between days 1 and 7, ie, early after chemotherapy. None ofthem had circulating tumor cells beyond day 9 after chemotherapy (Table 2 ). In contrast, in patients with BM infiltration, kinetic analyses displayed a different pattern of tumor cell recruitment, which occurred concomitant to the mobilization of PBPCs, ie, between days 9 and 16 after chemotherapy (Fig 2, Table 2 ).13 Moreover, in three of these patients, tumor cells were also detected early after chemotherapy, ie, between days 1 and 7. Thus, in some patients with BM disease, there was a mobilization of circulating tumor cells in two phases, with a partial clearance between days 5 and 10. The overall frequency of tumor cell mobilization in patients without marrow disease was 13% (5 of 38 patients), whereas all patients with BM infiltrating tumors (n = 8) recruited tumor cells after VIP chemotherapy (Table 2) .
Tumor cells were mobilized only in patients with extensive-disease SCLC (5/ I O = 50%), in patients with stage IV breast cancer (7/7 = loo%), as well as in one patient with advanced NSCLC (Table l) We have shown in this report that tumor cell mobilization actually takes place. In all patients with circulating tumor cells under steady-state conditions, the number of tumor cells is increased upon recruitment of PBPCs. In patients with no proof of baseline tumor cells in peripheral blood, the overall detection rate upon mobilization of PBPCs is 21% (9/42 patients), with the highest probability being documented in patients with stage IV breast cancer and extensive-disease small-cell lung cancer.
The mechanisms that underlay tumor cell recruitment are unknown. Interestingly, two different patterns of tumor cell mobilization were seen. The first phase of tumor cell recruitment seen early after chemotherapy might represent tumor cells that have been released from rapidly responding tumor areas. The second pattern of recruitment (corresponding to the time of peak output of progenitor cells) was only observed in patients with BM disease, suggesting that these tumor cells might have been mobilized from the marrow, concomitant with hematopoietic progenitor cells. Possibly, tumor cells that metastasize to BM may share some of the characteristics of hematopoietic progenitor cells, such as homing receptors or adhesion molecules.
Recruitment of tumor cells was observed after chemotherapy + G-CSF, a procedure that several groups including our own have shown to be highly effective in mobilizing PBPCS.~." The relative contribution of chemotherapy and G-CSF with respect to the mobilization oftumor cells is unclear at this point; we are testing in a current protocol whether tumor cells are also recruited when G-CSF is administered alone for the mobilization of PBPCs.
We have no evidence that tumor cells detected by the immunocytologic method used represent normal epithelial cells which might have been disrupted from normal tissue in conjunction with chemotherapy, because tumor cell mobilization was only observed in breast and SCLC patients. 
Days after VIP Chemotherapy
All other patients who were treated according to the same chemotherapy regimen were negative for tumor cells; however, numbers in the other tumor categories studied are still too small to permit a definitive conclusion. BM as well as peripheral blood samples from patients with nonmalignant disease are consistently negative both in our own studies as well as in published data.20
Clearance of circulating tumor cells was observed after one additional cycle of the same VIP chemotherapy in all SCLC patients, whereas in breast cancer patients tumor cells were still detectable, though in reduced numbers, in two of seven patients. This observation suggests that induction chemotherapy should be administered before PBPCs are mobilized and harvested. However, considering the possibility that tumor cells develop chemoresistance before application of a high-dose regimen, and because quality and quantity of PBPCs decrease with increasing doses of prior chemotherapy and/or radiotherapy," progenitor cell harvest should not be delayed too long.
The biologic significance of tumor cells contaminating PBPC preparations is unknown. It might be possible that circulating tumor cells primarily reflect advanced stage disease, and long-term prognosis essentially is related to the underlying disease and not to the number of retransfused tumor cells contaminating PBPC harvests.
For autologous BM transplantation, it has been shown by Gribben et aI2' in B-cell lymphomas and by Brenner et a12* in childhood acute myelogenous leukemia (AML) that reinfusion of tumor cells might be an important prognostic indicator in predicting relapse. However, for solid tumors and for autografting with PBPCs, data are missing. Thus, at present it cannot be estimated whether a positive selection of hematopoietic progenitor cells and/or the depletion of tumor cells from PBPC harvests affects clinical outcome. We would prefer to currently treat patients with PBPCs that have been depleted of contaminating tumor cells, either by retransfusing positively selected CD34' progenitor ~e l l s~~.~~ and/or by ex vivo expanding progenitor cells with the po-
